Showing results (11-20 of 38) with videos related to

Sort By:
Pageof 4
Bioanalysis|November 26, 2016
SRM-based measurements of proprotein convertase subtilisin/kexin type 9 and lipoprotein(a) kinetics in nonhuman primate serumFang Xie, Maurice G Emery, John P Gibbs, et al.
Cancer Chemotherapy and Pharmacology|January 5, 2021
Dose adjustment of venetoclax when co-administered with posaconazole: clinical drug-drug interaction predictions using a PBPK approachSumit Bhatnagar, Dwaipayan Mukherjee, Ahmed Hamed Salem, et al.
Journal of Clinical Pharmacology|December 19, 2018
Accelerating Drug Development in Pediatric Oncology With the Clinical Pharmacology StorehouseMohamad Shebley, Rajeev M Menon, John P Gibbs, et al.
CPT: Pharmacometrics & Systems Pharmacology|September 25, 2018
Receiver Operating Characteristic Analysis and Clinical Trial Simulation to Inform Dose Titration DecisionsJohn David Clements, Juan Jose Perez Ruixo, John P Gibbs, et al.
Clinical Pharmacokinetics|May 17, 2017
Population Pharmacokinetic and Pharmacodynamic Modeling of Etelcalcetide in Patients with Chronic Kidney Disease and Secondary Hyperparathyroidism Receiving HemodialysisPing Chen, Adimoolam Narayanan, Benjamin Wu, et al.
Journal of Pharmacokinetics and Pharmacodynamics|May 9, 2018
Population pharmacokinetics and exposure-response modeling and simulation for evolocumab in healthy volunteers and patients with hypercholesterolemiaMita Kuchimanchi, Anita Grover, Maurice G Emery, et al.
Journal of Clinical Pharmacology|December 14, 2011
Quantitative model of the relationship between dipeptidyl peptidase-4 (DPP-4) inhibition and response: meta-analysis of alogliptin, saxagliptin, sitagliptin, and vildagliptin efficacy resultsJohn P Gibbs, Jill Fredrickson, Todd Barbee, et al.
Clinical Pharmacokinetics|January 22, 2018
Clinical Pharmacokinetics and Pharmacodynamics of Evolocumab, a PCSK9 InhibitorSreeneeranj Kasichayanula, Anita Grover, Maurice G Emery, et al.
JAMA Cardiology|January 26, 2017
Association Between Circulating Baseline Proprotein Convertase Subtilisin Kexin Type 9 Levels and Efficacy of EvolocumabNihar R Desai, Robert P Giugliano, Scott M Wasserman, et al.
Arthritis Research & Therapy|October 10, 2015
Safety, tolerability, pharmacokinetics, and efficacy of AMG 403, a human anti-nerve growth factor monoclonal antibody, in two phase I studies with healthy volunteers and knee osteoarthritis subjectsJason M Gow, Wayne H Tsuji, Gary J Williams, et al.
Pageof 4